A Phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma

William J. Berg; Lawrence H. Schwartz; Alison Amsterdam; Madhu Mazumdar; Vaia Vlamis; Teresa Murray Law; David M. Nanus; Robert J. Motzer

doi:10.1023/A:1005902022076

A Phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma

William J. Berg, Lawrence H. Schwartz, Alison Amsterdam, Madhu Mazumdar, Vaia Vlamis, Teresa Murray Law, David M. Nanus, Robert J. Motzer

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

The aim of this study was to determine the antitumor activity of 13-cis-retinoic acid as a single agent in patients with advanced renal cell carcinoma. Eligible patients had advanced renal cell carcinoma with bi-dimensionally measurable disease, a Karnofsky performance status of at least 70, life expectancy of greater than three months, no evidence of brain metastases, and treatment with no more than one chemotherapy regimen. Patients were treated with one mg/kg/day of 13-cis-retinoic acid orally. Twenty-six patients were enrolled in this study and 25 were evaluable for response and toxicity. Of the twenty-five evaluable patients, no major responses were achieved. Toxicity was mild, with no patient requiring a dose reduction. At the dose administered in this trial, 13-cis-retinoic acid is inactive as a single agent in renal cell carcinoma.

Original language	English
Pages (from-to)	353-355
Number of pages	3
Journal	Investigational New Drugs
Volume	15
Issue number	4
DOIs	https://doi.org/10.1023/A:1005902022076
State	Published - 1997
Externally published	Yes

Keywords

Advanced renal cell carcinoma
Retinoic acid

Access to Document

10.1023/A:1005902022076

Cite this

@article{61b4bb84c4a4449aa83bef731c7b4a5a,

title = "A Phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma",

abstract = "The aim of this study was to determine the antitumor activity of 13-cis-retinoic acid as a single agent in patients with advanced renal cell carcinoma. Eligible patients had advanced renal cell carcinoma with bi-dimensionally measurable disease, a Karnofsky performance status of at least 70, life expectancy of greater than three months, no evidence of brain metastases, and treatment with no more than one chemotherapy regimen. Patients were treated with one mg/kg/day of 13-cis-retinoic acid orally. Twenty-six patients were enrolled in this study and 25 were evaluable for response and toxicity. Of the twenty-five evaluable patients, no major responses were achieved. Toxicity was mild, with no patient requiring a dose reduction. At the dose administered in this trial, 13-cis-retinoic acid is inactive as a single agent in renal cell carcinoma.",

keywords = "Advanced renal cell carcinoma, Retinoic acid",

author = "Berg, {William J.} and Schwartz, {Lawrence H.} and Alison Amsterdam and Madhu Mazumdar and Vaia Vlamis and Law, {Teresa Murray} and Nanus, {David M.} and Motzer, {Robert J.}",

year = "1997",

doi = "10.1023/A:1005902022076",

language = "English",

volume = "15",

pages = "353--355",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Springer",

number = "4",

}

TY - JOUR

T1 - A Phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma

AU - Berg, William J.

AU - Schwartz, Lawrence H.

AU - Amsterdam, Alison

AU - Mazumdar, Madhu

AU - Vlamis, Vaia

AU - Law, Teresa Murray

AU - Nanus, David M.

AU - Motzer, Robert J.

PY - 1997

Y1 - 1997

N2 - The aim of this study was to determine the antitumor activity of 13-cis-retinoic acid as a single agent in patients with advanced renal cell carcinoma. Eligible patients had advanced renal cell carcinoma with bi-dimensionally measurable disease, a Karnofsky performance status of at least 70, life expectancy of greater than three months, no evidence of brain metastases, and treatment with no more than one chemotherapy regimen. Patients were treated with one mg/kg/day of 13-cis-retinoic acid orally. Twenty-six patients were enrolled in this study and 25 were evaluable for response and toxicity. Of the twenty-five evaluable patients, no major responses were achieved. Toxicity was mild, with no patient requiring a dose reduction. At the dose administered in this trial, 13-cis-retinoic acid is inactive as a single agent in renal cell carcinoma.

AB - The aim of this study was to determine the antitumor activity of 13-cis-retinoic acid as a single agent in patients with advanced renal cell carcinoma. Eligible patients had advanced renal cell carcinoma with bi-dimensionally measurable disease, a Karnofsky performance status of at least 70, life expectancy of greater than three months, no evidence of brain metastases, and treatment with no more than one chemotherapy regimen. Patients were treated with one mg/kg/day of 13-cis-retinoic acid orally. Twenty-six patients were enrolled in this study and 25 were evaluable for response and toxicity. Of the twenty-five evaluable patients, no major responses were achieved. Toxicity was mild, with no patient requiring a dose reduction. At the dose administered in this trial, 13-cis-retinoic acid is inactive as a single agent in renal cell carcinoma.

KW - Advanced renal cell carcinoma

KW - Retinoic acid

UR - http://www.scopus.com/inward/record.url?scp=0031414828&partnerID=8YFLogxK

U2 - 10.1023/A:1005902022076

DO - 10.1023/A:1005902022076

M3 - Article

C2 - 9547678

AN - SCOPUS:0031414828

SN - 0167-6997

VL - 15

SP - 353

EP - 355

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 4

ER -

A Phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma

Abstract

Keywords

Access to Document

Fingerprint

Cite this